1
|
Zhao W, Wang X, Li Y, Li Y. Administration with Vaccinia Virus Encoding Canine Parvovirus 2 vp2 Elicits Systemic Immune Responses in Mice and Dogs. Viral Immunol 2020; 33:434-443. [PMID: 32364832 DOI: 10.1089/vim.2019.0164] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Canine parvovirus type 2 (CPV2) is a highly contagious cause of serious and often fatal disease in young dogs. Despite the widespread availability of attenuated vaccines, safer, more stable, and more effective CPV2 vaccine candidates are still under exploration. Vaccinia virus (VV) has already been proved to be a safe, stable, and effective vaccine vector. In this study, we generated a VV-based CPV2 vaccine candidate (VV-CPV-VP2) and then evaluated its immunogenicity in mice and dogs. The exogenous vp2 gene of CPV2, which replaced the major virulence gene hemagglutinin (ha) of VV, expressed efficiently and stably in vitro. Subsequently, intramuscular immunization of mice induced robust and lasting systemic immune responses, including neutralizing antibody against both CPV2a and CPV2b, and CPV2-VP2-specific interferon gamma (IFN-γ) secreting T cell. In addition, administration with a high-dose of VV-CPV-VP2 did not cause significant side effects for mice, thus indicating marked safety of this vaccine candidate. Most importantly, a single-dose vaccination of VV-CPV2-VP2 elicited substantial antibody responses and provided comparable protection for dogs with attenuated CPV2 vaccine. Collectively, this study demonstrated that VV-CPV2-VP2 could be used as a promising vaccine candidate preventing CPV2 from infection for dogs.
Collapse
Affiliation(s)
- Wanbo Zhao
- Hubei Engineering Research Center of Viral Vector, Applied Biotechnology Research Center, Wuhan University of Bioengineering, Wuhan, China
| | - Xiaomei Wang
- Hubei Engineering Research Center of Viral Vector, Applied Biotechnology Research Center, Wuhan University of Bioengineering, Wuhan, China
| | - Yi Li
- Hubei Engineering Research Center of Viral Vector, Applied Biotechnology Research Center, Wuhan University of Bioengineering, Wuhan, China
| | - Yaoming Li
- Hubei Engineering Research Center of Viral Vector, Applied Biotechnology Research Center, Wuhan University of Bioengineering, Wuhan, China
| |
Collapse
|
2
|
Kozlov ON, Mitiouchkina TY, Tarasenko IV, Shaloiko LA, Firsov AP, Dolgov SV. Agrobacterium-Mediated Transformation of Lemna minor L. with Hirudin and β-Glucuronidase Genes. APPL BIOCHEM MICRO+ 2019. [DOI: 10.1134/s0003683819080076] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
3
|
Beihaghi M, Marashi H, Bagheri A, Sankian M. Transient expression of CCL21as recombinant protein in tomato. ACTA ACUST UNITED AC 2017; 17:10-15. [PMID: 29276695 PMCID: PMC5730375 DOI: 10.1016/j.btre.2017.11.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2017] [Revised: 10/04/2017] [Accepted: 11/24/2017] [Indexed: 01/13/2023]
Abstract
Applied use of plants as bioreactors for production of recombinant proteins. The present study is the first to report gene expression of ccl21 construct in tomato via agro infiltration to use this plant as oral vaccine. To investigate the role of this protein in anti-metastatic function on cancer cells
The main goal of this study was to investigate the possibility of expressing recombinant protein of C-C chemokine ligand 21 (CCL21) in Solanum lycopersicum via agroinfiltration. CCL21 is a chemokine can be used for anti-metastatic of cancer cell lines. To examine the expression of CCL21 protein in S. lycopersicum, the construct of ccl21 was synthesized. This construct was cloned into pBI121 and the resulting CCL21 plasmid was agro-infiltrated into S. lycopersicum leaves. Within three days after infiltration, Expression of the foreign gene was confirmed by quantitative Real-time PCR. A recombinant CCL21 protein was immunogenically detected by western blot, dot blot and ELISA assay. And results showed that the foreign gene was expressed in the transformed leaves in high level. Also scratch assay was used to investigate the role of this protein in anti-metastatic function. The results demonstrated anti-metastatic of cancer cells in the presence of this protein.
Collapse
Affiliation(s)
- Maria Beihaghi
- College of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran
| | - Hasan Marashi
- College of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran
- Corresponding author at: Hasan MarashiCollege of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran.College of AgricultureFerdowsi University of MashhadMashhadIran
| | - Abdolreza Bagheri
- College of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran
| | - Mojtaba Sankian
- BuAli Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
4
|
Kar B, Mohapatra A, Mohanty J, Sahoo PK. Evaluation of ribosomal P0 peptide as a vaccine candidate against Argulus siamensis in Labeo rohita. Open Life Sci 2017. [DOI: 10.1515/biol-2017-0011] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
AbstractArgulusspp. are important ectoparasites of fish, and the current approach of their control using chemical pesticides has numerous drawbacks. Vaccination is a promising alternative but identification of protective antigens is a limiting step. The ribosomal protein P0, essential for protein synthesis, has been studied as a vaccine candidate. We generated sequence information of the P0 protein of the ectoparasiteArgulus siamensisand the hostLabeo rohita. The region of the parasite P0 protein with less sequence similarity with that of the host P0 protein and high predicted antigenicity was used for peptide synthesis. The peptide was conjugated with keyhole limpet hemocyanin (KLH) for immunization of rohu at a dose of 1.5 μg/g body weight. Dot blot assays confirmed production of antibodies against pP0-KLH in immunized fish. We evaluated the efficiency of pP0-KLH as a vaccine antigen by challenge of the immunized fish withA.siamensis. Although there was no significant difference in parasite load between both groups, a reduced and delayed mortality of 59% (15 days post-infection) in immunized group was noticed as compared to 75% mortality (within 7–15 days post-infection) in control group. The partial protection observed indicated the need for further optimization of this molecule to develop it into a vaccine candidate.
Collapse
Affiliation(s)
- Banya Kar
- Fish Health Management Division, ICAR-Central Institute of Freshwater Aquaculture, Kausalyaganga, Bhubaneswar-751 002, Odisha, India
| | - Amruta Mohapatra
- Fish Health Management Division, ICAR-Central Institute of Freshwater Aquaculture, Kausalyaganga, Bhubaneswar-751 002, Odisha, India
| | - Jyotirmaya Mohanty
- Fish Genetics and Biotechnology Division, ICAR-Central Institute of Freshwater Aquaculture, Kausalyaganga, Bhubaneswar-751 002, Odisha, India
| | - Pramoda Kumar Sahoo
- Fish Health Management Division, ICAR-Central Institute of Freshwater Aquaculture, Kausalyaganga, Bhubaneswar-751 002, Odisha, India
| |
Collapse
|
5
|
Firsov A, Tarasenko I, Mitiouchkina T, Ismailova N, Shaloiko L, Vainstein A, Dolgov S. High-Yield Expression of M2e Peptide of Avian Influenza Virus H5N1 in Transgenic Duckweed Plants. Mol Biotechnol 2016; 57:653-61. [PMID: 25740321 DOI: 10.1007/s12033-015-9855-4] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Avian influenza is a major viral disease in poultry. Antigenic variation of this virus hinders vaccine development. However, the extracellular domain of the virus-encoded M2 protein (peptide M2e) is nearly invariant in all influenza A strains, enabling the development of a broad-range vaccine against them. Antigen expression in transgenic plants is becoming a popular alternative to classical expression methods. Here we expressed M2e from avian influenza virus A/chicken/Kurgan/5/2005(H5N1) in nuclear-transformed duckweed plants for further development of avian influenza vaccine. The N-terminal fragment of M2, including M2e, was selected for expression. The M2e DNA sequence fused in-frame to the 5' end of β-glucuronidase was cloned into pBI121 under the control of CaMV 35S promoter. The resulting plasmid was successfully used for duckweed transformation, and western analysis with anti-β-glucuronidase and anti-M2e antibodies confirmed accumulation of the target protein (M130) in 17 independent transgenic lines. Quantitative ELISA of crude protein extracts from these lines showed M130-β-glucuronidase accumulation ranging from 0.09-0.97 mg/g FW (0.12-1.96 % of total soluble protein), equivalent to yields of up to 40 μg M2e/g plant FW. This relatively high yield holds promise for the development of a duckweed-based expression system to produce an edible vaccine against avian influenza.
Collapse
Affiliation(s)
- Aleksey Firsov
- Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the RAS, Prospekt Nauki, 6, Pushchino, Moscow region, Russian Federation, 142290,
| | | | | | | | | | | | | |
Collapse
|
6
|
Abstract
Ticks are responsible for the transmission of viral, bacterial, and protozoal diseases of man and animals and also produce significant economic losses to cattle industry. The use of acaricides constitutes a major component of integrated tick control strategies. However, this is accompanied by the selection of acaricide-resistant ticks and contamination of environment and milk and meat products with drug residues. These issues highlight the need for alternative approaches to control tick infestations and have triggered the search for tick protective antigens for vaccine development. Vaccination as a tick control method has been practiced since the introduction of TickGARD and Gavac that were developed using the midgut glycoprotein Bm86 as antigen. Gavac within integrated tick management systems has proven to reduce the number of acaricidal applications per year that are required to control some strains of R. microplus ticks in different geographical regions. Nevertheless, it has limited or no efficacy against other tick species. These issues have stimulated research for additional tick protective antigens with critical functions in the tick. This chapter presents methodologies for the design and test of molecules as antigens against ticks. Considerations about different methods for the tick control compared to the immunological methods, the desirable characteristics for an anti-tick vaccine and the obstacles encountered for developing this kind of vaccines are discussed. Detailed methodologies for the establishment of a biological model to test new molecules as immunogens against ticks and to perform challenge trials with this model are presented. General considerations in the efficacy calculation for any anti-tick vaccine are also discussed.
Collapse
Affiliation(s)
- Alina Rodríguez-Mallon
- Animal Biotechnology Department, Center for Genetic Engineering and Biotechnology, Avenue 31 between 158 and 190, P.O. Box 6162, Havana, 10600, Cuba.
| |
Collapse
|
7
|
Jin H, Xia X, Liu B, Fu Y, Chen X, Wang H, Xia Z. High-yield production of canine parvovirus virus-like particles in a baculovirus expression system. Arch Virol 2015; 161:705-10. [PMID: 26666439 DOI: 10.1007/s00705-015-2719-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Accepted: 12/02/2015] [Indexed: 10/22/2022]
Abstract
An optimized VP2 gene from the current prevalent CPV strain (new CPV-2a) in China was expressed in a baculovirus expression system. It was found that the VP2 proteins assembled into virus-like particles (VLPs) with antigenic properties similar to those of natural CPV and with an especially high hemagglutination (HA) titer (1:2(20)). Dogs intramuscularly or orally immunized with VLPs produced antibodies against CPV with >1:80 hemagglutination inhibition (HI) units for at least 3 months. The CPV VLPs could be considered for use as a vaccine against CPV or as a platform for research on chimeric VLP vaccines against other diseases.
Collapse
Affiliation(s)
- Hongli Jin
- Changchun SR Biological Technology Co., LTD, Changchun, 130012, China.
| | - Xiaohong Xia
- Changchun SR Biological Technology Co., LTD, Changchun, 130012, China
| | - Bing Liu
- Changchun SR Biological Technology Co., LTD, Changchun, 130012, China
| | - Yu Fu
- Changchun SR Biological Technology Co., LTD, Changchun, 130012, China
| | - Xianping Chen
- Changchun SR Biological Technology Co., LTD, Changchun, 130012, China
| | - Huihui Wang
- Changchun SR Biological Technology Co., LTD, Changchun, 130012, China
| | - Zhenqiang Xia
- Changchun SR Biological Technology Co., LTD, Changchun, 130012, China.
| |
Collapse
|
8
|
Dudognon B, Romero-Santacreu L, Gómez-Sebastián S, Hidalgo AB, López-Vidal J, Bellido ML, Muñoz E, Escribano JM. Production of functional active human growth factors in insects used as living biofactories. J Biotechnol 2014; 184:229-39. [PMID: 24915129 DOI: 10.1016/j.jbiotec.2014.05.030] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Revised: 05/23/2014] [Accepted: 05/30/2014] [Indexed: 12/11/2022]
Abstract
Growth factors (GFs) are naturally signalling proteins, which bind to specific receptors on the cell surface. Numerous families of GFs have already been identified and remarkable progresses have been made in understanding the pathways that these proteins use to activate/regulate the complex signalling network involved in cell proliferation or wound healing processes. The bottleneck for a wider clinical and commercial application of these factors relay on their scalable cost-efficient production as bioactive molecules. The present work describes the capacity of Trichoplusia ni insect larvae used as living bioreactors in combination with the baculovirus vector expression system to produce three fully functional human GFs, the human epidermal growth factor (huEGF), the human fibroblast growth factor 2 (huFGF2) and the human keratinocyte growth factor 1 (huKGF1). The expression levels obtained per g of insect biomass were of 9.1, 2.6 and 3mg for huEGF, huFGF2 and huKGF1, respectively. Attempts to increase the productivity of the insect/baculovirus system we have used different modifications to optimize their production. Additionally, recombinant proteins were expressed fused to different tags to facilitate their purification. Interestingly, the expression of huKGF1 was significantly improved when expressed fused to the fragment crystallizable region (Fc) of the human antibody IgG. The insect-derived recombinant GFs were finally characterized in terms of biological activity in keratinocytes and fibroblasts. The present work opens the possibility of a cost-efficient and scalable production of these highly valuable molecules in a system that favours its wide use in therapeutic or cosmetic applications.
Collapse
Affiliation(s)
- Benoit Dudognon
- Alternative Gene Expression S.L. (ALGENEX), Centro empresarial, Parque Científico y Tecnológico de la Universidad Politécnica de Madrid, Campus de Montegancedo, Pozuelo de Alarcón, 28223 Madrid, Spain
| | - Lorena Romero-Santacreu
- Alternative Gene Expression S.L. (ALGENEX), Centro empresarial, Parque Científico y Tecnológico de la Universidad Politécnica de Madrid, Campus de Montegancedo, Pozuelo de Alarcón, 28223 Madrid, Spain
| | - Silvia Gómez-Sebastián
- Alternative Gene Expression S.L. (ALGENEX), Centro empresarial, Parque Científico y Tecnológico de la Universidad Politécnica de Madrid, Campus de Montegancedo, Pozuelo de Alarcón, 28223 Madrid, Spain
| | - Ana B Hidalgo
- Vivacell Biotechnology España S.L. Parque Científico Tecnológico Rabanales, 21, c/Cecilia Payne, Parcela ID 8.1, 14014 Córdoba, Spain
| | - Javier López-Vidal
- Alternative Gene Expression S.L. (ALGENEX), Centro empresarial, Parque Científico y Tecnológico de la Universidad Politécnica de Madrid, Campus de Montegancedo, Pozuelo de Alarcón, 28223 Madrid, Spain
| | - María L Bellido
- Vivacell Biotechnology España S.L. Parque Científico Tecnológico Rabanales, 21, c/Cecilia Payne, Parcela ID 8.1, 14014 Córdoba, Spain
| | - Eduardo Muñoz
- Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/Hospital Universitario Reina Sofía/Universidad de Córdoba, Córdoba, Spain
| | - José M Escribano
- Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Autovía A6, Km 7.5, 28040 Madrid, Spain.
| |
Collapse
|
9
|
Musiychuk K, Sivalenka R, Jaje J, Bi H, Flores R, Shaw B, Jones RM, Golovina T, Schnipper J, Khandker L, Sun R, Li C, Kang L, Voskinarian-Berse V, Zhang X, Streatfield S, Hambor J, Abbot S, Yusibov V. Plant-produced human recombinant erythropoietic growth factors support erythroid differentiation in vitro. Stem Cells Dev 2013; 22:2326-40. [PMID: 23517237 PMCID: PMC3730378 DOI: 10.1089/scd.2012.0489] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2012] [Accepted: 03/21/2013] [Indexed: 01/11/2023] Open
Abstract
Clinically available red blood cells (RBCs) for transfusions are at high demand, but in vitro generation of RBCs from hematopoietic stem cells requires significant quantities of growth factors. Here, we describe the production of four human growth factors: erythropoietin (EPO), stem cell factor (SCF), interleukin 3 (IL-3), and insulin-like growth factor-1 (IGF-1), either as non-fused proteins or as fusions with a carrier molecule (lichenase), in plants, using a Tobacco mosaic virus vector-based transient expression system. All growth factors were purified and their identity was confirmed by western blotting and peptide mapping. The potency of these plant-produced cytokines was assessed using TF1 cell (responsive to EPO, IL-3 and SCF) or MCF-7 cell (responsive to IGF-1) proliferation assays. The biological activity estimated here for the cytokines produced in plants was slightly lower or within the range cited in commercial sources and published literature. By comparing EC50 values of plant-produced cytokines with standards, we have demonstrated that all four plant-produced growth factors stimulated the expansion of umbilical cord blood-derived CD34+ cells and their differentiation toward erythropoietic precursors with the same potency as commercially available growth factors. To the best of our knowledge, this is the first report on the generation of all key bioactive cytokines required for the erythroid development in a cost-effective manner using a plant-based expression system.
Collapse
Affiliation(s)
| | | | - Jennifer Jaje
- Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware
| | - Hong Bi
- Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware
| | - Rosemary Flores
- Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware
| | - Brenden Shaw
- Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware
| | - R. Mark Jones
- Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware
| | - Tatiana Golovina
- Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware
| | | | | | - Ruiqiang Sun
- Celgene Cellular Therapeutics, Warren, New Jersey
| | - Chang Li
- Celgene Cellular Therapeutics, Warren, New Jersey
| | - Lin Kang
- Celgene Cellular Therapeutics, Warren, New Jersey
| | | | | | | | - John Hambor
- Celgene Cellular Therapeutics, Warren, New Jersey
| | | | - Vidadi Yusibov
- Fraunhofer USA Center for Molecular Biotechnology, Newark, Delaware
| |
Collapse
|
10
|
Larsen JS, Curtis WR. RNA viral vectors for improved Agrobacterium-mediated transient expression of heterologous proteins in Nicotiana benthamiana cell suspensions and hairy roots. BMC Biotechnol 2012; 12:21. [PMID: 22559055 PMCID: PMC3403893 DOI: 10.1186/1472-6750-12-21] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2012] [Accepted: 05/06/2012] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Plant cell suspensions and hairy root cultures represent scalable protein expression platforms. Low protein product titers have thus far limited the application of transient protein expression in these hosts. The objective of this work was to overcome this limitation by harnessing A. tumefaciens to deliver replicating and non-replicating RNA viral vectors in plant tissue co-cultures. RESULTS Replicating vectors derived from Potato virus X (PVX) and Tobacco rattle virus (TRV) were modified to contain the reporter gene β-glucuronidase (GUS) with a plant intron to prevent bacterial expression. In cell suspensions, a minimal PVX vector retaining only the viral RNA polymerase gene yielded 6.6-fold more GUS than an analogous full-length PVX vector. Transient co-expression of the minimal PVX vector with P19 of Tomato bushy stunt virus or HC-Pro of Tobacco etch virus to suppress post-transcriptional gene silencing increased GUS expression by 44 and 83%, respectively. A non-replicating vector containing a leader sequence from Cowpea mosaic virus (CPMV-HT) modified for enhanced translation led to 70% higher transient GUS expression than a control treatment. In hairy roots, a TRV vector capable of systemic movement increased GUS accumulation by 150-fold relative to the analogous PVX vector. Histochemical staining for GUS in TRV-infected hairy roots revealed the capacity for achieving even higher productivity per unit biomass. CONCLUSIONS For the first time, replicating PVX vectors and a non-replicating CPMV-HT vector were successfully applied toward transient heterologous protein expression in cell suspensions. A replicating TRV vector achieved transient GUS expression levels in hairy roots more than an order of magnitude higher than the highest level previously reported with a viral vector delivered by A. tumefaciens.
Collapse
Affiliation(s)
- Jeffrey S Larsen
- Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania, 16802, USA
| | - Wayne R Curtis
- Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania, 16802, USA
| |
Collapse
|
11
|
Rodríguez-Mallon A, Fernández E, Encinosa PE, Bello Y, Méndez-Pérez L, Ruiz LC, Pérez D, González M, Garay H, Reyes O, Méndez L, Estrada MP. A novel tick antigen shows high vaccine efficacy against the dog tick, Rhipicephalus sanguineus. Vaccine 2012; 30:1782-9. [PMID: 22245603 DOI: 10.1016/j.vaccine.2012.01.011] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2011] [Revised: 01/03/2012] [Accepted: 01/04/2012] [Indexed: 11/28/2022]
Abstract
Ticks are acaridae ectoparasites that, while taking a blood meal, can transmit viruses, bacteria, protozoa and filarial nematodes, which cause a variety of human and animal illnesses. The use of chemical pesticides constitutes the primary measure for control of these ectoparasites. However, the intensive use of these chemicals has drawbacks such as the contamination of food, environmental pollution and development of resistance by ectoparasites. Vaccination is considered a promising alternative for controlling infestations by ectoparasites. Although emerging tick proteins have been identified recently, and have been proposed as potential targets for generating protective molecules, only a limited number of them have been evaluated in vaccine trials. More than 80 proteins are found in eukaryotic ribosomes. The protein P0 is essential for the assembly of the 60S ribosomal subunit. We have identified an immunogenic region of the ribosomal protein P0 from Rhipicephalus sp. ticks that is not very conserved compared to host P0. The efficacy of a 20 amino acid synthetic peptide from this sequence was assayed as a vaccine antigen against Rhipicephalus sanguineus infestations in an immunization and challenge experiment on rabbits. A remarkable diminution in the viability of newly molted nymphs from larvae fed on vaccinated rabbits was observed. The number of adults and the number of eggs hatching were significantly reduced, with an overall efficacy of 90%. Our results demonstrated that immunization with an immunogenic peptide of tick protein P0 greatly reduced survival of ticks, suggesting that it has promise as an effective tick control agent.
Collapse
Affiliation(s)
- Alina Rodríguez-Mallon
- Animal Biotechnology Department, Center for Genetic Engineering and Biotechnology, 31th Avenue and 190, P.O. Box 6162, Havana 10600, Cuba.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Lee C, Chung KW, Kim TS, Choi KM, Choi YK, Chung NJ, Rhie HG, Lee HS, Lee SJ, Lee HW. Trials for the co-expression of the merozoite surface protein-1 and circumsporozoite protein genes of Plasmodium vivax. Exp Parasitol 2011; 129:227-33. [PMID: 21907198 DOI: 10.1016/j.exppara.2011.08.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Revised: 08/16/2011] [Accepted: 08/17/2011] [Indexed: 12/31/2022]
Abstract
Merozoite surface protein-1 (MSP-1), a major asexual blood stage antigen, and circumsporozoite protein (CSP), a component of sporozoites that includes a Plasmodium vivax B-cell epitope, are strong candidates for use in a malaria vaccine. A chimeric recombinant gene containing portions of both msp-1 and csp from P. vivax separated by Pro-Gly linker motif was generated. The construct gene was named mlc (msp-1, linker, and csp). The MLC chimeric recombinant protein had a molecular weight of approximately 25 kDa when expressed in Escherichia coli, as determined with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. The purified chimeric protein reacted with the sera of patients infected with P. vivax but not with the sera of uninfected patients according to western blot analysis. The chimeric protein reacted well with sera of malaria patients (109/115, 94.78%) as assessed with enzyme-linked immunosorbent assay (ELISA). BALB/c mice that were orally immunized with the MLC chimeric recombinant protein successfully produced antigen-specific antibodies. Additionally, levels of the Th1-associated cytokines IL-12(p40), TNF-α, and IFN-γ were significantly increased in the spleens of the BALB/c mice. Therefore, the E. coli-expressed MLC chimeric recombinant protein might be used as a valuable vaccine candidate for oral immunization against vivax malaria.
Collapse
Affiliation(s)
- Choonghee Lee
- Institute of Global Environment and Department of Biology, Kyung Hee University, Seoul 130-701, Republic of Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Conley AJ, Joensuu JJ, Richman A, Menassa R. Protein body-inducing fusions for high-level production and purification of recombinant proteins in plants. PLANT BIOTECHNOLOGY JOURNAL 2011; 9:419-33. [PMID: 21338467 DOI: 10.1111/j.1467-7652.2011.00596.x] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
For the past two decades, therapeutic and industrially important proteins have been expressed in plants with varying levels of success. The two major challenges hindering the economical production of plant-made recombinant proteins include inadequate accumulation levels and the lack of efficient purification methods. To address these limitations, several fusion protein strategies have been recently developed to significantly enhance the production yield of plant-made recombinant proteins, while simultaneously assisting in their subsequent purification. Elastin-like polypeptides are thermally responsive biopolymers composed of a repeating pentapeptide 'VPGXG' sequence that are valuable for the purification of recombinant proteins. Hydrophobins are small fungal proteins capable of altering the hydrophobicity of their respective fusion partner, thus enabling efficient purification by surfactant-based aqueous two-phase systems. Zera, a domain of the maize seed storage protein γ-zein, can induce the formation of protein storage bodies, thus facilitating the recovery of fused proteins using density-based separation methods. These three novel protein fusion systems have also been shown to enhance the accumulation of a range of different recombinant proteins, while concurrently inducing the formation of protein bodies. The packing of these fusion proteins into protein bodies may exclude the recombinant protein from normal physiological turnover. Furthermore, these systems allow for quick, simple and inexpensive nonchromatographic purification of the recombinant protein, which can be scaled up to industrial levels of protein production. This review will focus on the similarities and differences of these artificial storage organelles, their biogenesis and their implication for the production of recombinant proteins in plants and their subsequent purification.
Collapse
Affiliation(s)
- Andrew J Conley
- Southern Crop Protection and Food Research Centre, Agriculture and Agri-Food Canada, London, ON, Canada
| | | | | | | |
Collapse
|
14
|
Murine immune responses to a Plasmodium vivax-derived chimeric recombinant protein expressed in Brassica napus. Malar J 2011; 10:106. [PMID: 21529346 PMCID: PMC3098821 DOI: 10.1186/1475-2875-10-106] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2011] [Accepted: 04/29/2011] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND To develop a plant-based vaccine against Plasmodium vivax, two P. vivax candidate proteins were chosen. First, the merozoite surface protein-1 (MSP-1), a major asexual blood stage antigen that is currently considered a strong vaccine candidate. Second, the circumsporozoite protein (CSP), a component of sporozoites that contains a B-cell epitope. METHODS A synthetic chimeric recombinant 516 bp gene encoding containing PvMSP-1, a Pro-Gly linker motif, and PvCSP was synthesized; the gene, named MLC, encoded a total of 172 amino acids. The recombinant gene was modified with regard to codon usage to optimize gene expression in Brassica napus. The Ti plasmid inducible gene transfer system was used for MLC chimeric recombinant gene expression in B. napus. Gene expression was confirmed by polymerase chain reaction (PCR), beta-glucuronidase reporter gene (GUS) assay, and Western blot. RESULTS The MLC chimeric recombinant protein expressed in B. napus had a molecular weight of approximately 25 kDa. It exhibited a clinical sensitivity of 84.21% (n=38) and a clinical specificity of 100% (n=24) as assessed by enzyme-linked immunosorbent assay (ELISA). Oral immunization of BALB/c mice with MLC chimeric recombinant protein successfully induced antigen-specific IgG1 production. Additionally, the Th1-related cytokines IL-12 (p40), TNF, and IFN-γ were significantly increased in the spleens of the BALB/c mice. CONCLUSIONS The chimeric MLC recombinant protein produced in B. napus has potential as both as an antigen for diagnosis and as a valuable vaccine candidate for oral immunization against vivax malaria.
Collapse
|
15
|
Brun A, Bárcena J, Blanco E, Borrego B, Dory D, Escribano JM, Le Gall-Reculé G, Ortego J, Dixon LK. Current strategies for subunit and genetic viral veterinary vaccine development. Virus Res 2011; 157:1-12. [PMID: 21316403 DOI: 10.1016/j.virusres.2011.02.006] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2010] [Revised: 02/03/2011] [Accepted: 02/04/2011] [Indexed: 12/24/2022]
Abstract
Developing vaccines for livestock provides researchers with the opportunity to perform efficacy testing in the natural hosts. This enables the evaluation of different strategies, including definition of effective antigens or antigen combinations, and improvement in delivery systems for target antigens so that protective immune responses can be modulated or potentiated. An impressive amount of knowledge has been generated in recent years on vaccine strategies and consequently a wide variety of antigen delivery systems is now available for vaccine research. This paper reviews several antigen production and delivery strategies other than those based on the use of live viral vectors. Genetic and protein subunit vaccines as well as alternative production systems are considered in this review.
Collapse
Affiliation(s)
- Alejandro Brun
- Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos, 28130 Madrid, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Gil F, Pérez-Filgueira M, Barderas MG, Pastor-Vargas C, Alonso C, Vivanco F, Escribano JM. Targeting antigens to an invariant epitope of the MHC Class II DR molecule potentiates the immune response to subunit vaccines. Virus Res 2011; 155:55-60. [DOI: 10.1016/j.virusres.2010.08.022] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2010] [Revised: 08/23/2010] [Accepted: 08/24/2010] [Indexed: 10/19/2022]
|
17
|
Davies HM. Review article: commercialization of whole-plant systems for biomanufacturing of protein products: evolution and prospects. PLANT BIOTECHNOLOGY JOURNAL 2010; 8:845-861. [PMID: 20731788 DOI: 10.1111/j.1467-7652.2010.00550.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Technology for enabling plants to biomanufacture nonnative proteins in commercially significant quantities has been available for just over 20 years. During that time, the agricultural world has witnessed rapid commercialization and widespread adoption of transgenic crops enhanced for agronomic performance (herbicide-tolerance, insect-resistance), while plant-made pharmaceuticals (PMPs) and plant-made industrial products (PMIPs) have been limited to experimental and small-scale commercial production. This difference in the rate of commercial implementation likely reflects the very different business-development challenges associated with 'product' technologies compared with 'enabling' ('platform') technologies. However, considerable progress has been made in advancing and refining plant-based production of proteins, both technologically and in regard to identifying optimal business prospects. This review summarizes these developments, contrasting today's technologies and prospective applications with those of the industry's formative years, and suggesting how the PM(I)P industry's evolution has generated a very positive outlook for the 'plant-made' paradigm.
Collapse
Affiliation(s)
- H Maelor Davies
- Kentucky Tobacco Research and Development Center, and Department of Plant and Soil Sciences, University of Kentucky, Lexington, KY, USA.
| |
Collapse
|
18
|
Ortigosa SM, Fernández-San Millán A, Veramendi J. Stable production of peptide antigens in transgenic tobacco chloroplasts by fusion to the p53 tetramerisation domain. Transgenic Res 2010; 19:703-9. [PMID: 19953346 DOI: 10.1007/s11248-009-9348-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2009] [Accepted: 11/21/2009] [Indexed: 01/21/2023]
Abstract
The production of short peptides as single molecules in recombinant systems is often limited by the low stability of the foreign peptide. In the plant expression system this problem has been solved by translational fusions to recombinant proteins that are highly stable or are able to form complex structures. Previously, we demonstrated that the highly immunogenic 21 amino acid peptide 2L21, which is derived from the canine parvovirus (CPV) VP2 protein, did not accumulate in transgenic tobacco chloroplasts. In this report, we translationally fused the 2L21 peptide to the 42 amino acid tetramerisation domain (TD) from the human transcription factor p53. The chimaeric 2L21-TD protein was expressed in tobacco chloroplasts. Leaves accumulated high levels of the recombinant protein (up to 0.4 mg/g fresh weight of leaf material, equivalent to ~6% of total soluble protein; 2% considering only the 2L21 peptide). The 2L21-TD protein was able to form tetramers in the stroma of the chloroplast. Mice immunised intraperitoneally with partially purified leaf extracts containing the 2L21-TD protein developed specific antibodies with titres similar to those elicited by a previously reported fusion between 2L21 and the B subunit of the cholera toxin. Mouse sera were able to detect both the 2L21 synthetic peptide and the CPV VP2 protein, showing that the antigenicity of the 2L21 epitope was preserved in the chimaeric protein. These results demonstrate that the p53 TD can be used as a carrier molecule for the accumulation of short peptides (such as 2L21) in the chloroplast without altering the immunogenic properties of the peptide.
Collapse
Affiliation(s)
- Susana M Ortigosa
- Instituto de Agrobiotecnología, Universidad Pública de Navarra-CSIC-Gobierno de Navarra, Campus de Arrosadía, 31006, Pamplona, Spain
| | | | | |
Collapse
|
19
|
Joensuu JJ, Conley AJ, Lienemann M, Brandle JE, Linder MB, Menassa R. Hydrophobin fusions for high-level transient protein expression and purification in Nicotiana benthamiana. PLANT PHYSIOLOGY 2010; 152:622-33. [PMID: 20018596 PMCID: PMC2815860 DOI: 10.1104/pp.109.149021] [Citation(s) in RCA: 122] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/08/2009] [Accepted: 12/05/2009] [Indexed: 05/17/2023]
Abstract
Insufficient accumulation levels of recombinant proteins in plants and the lack of efficient purification methods for recovering these valuable proteins have hindered the development of plant biotechnology applications. Hydrophobins are small and surface-active proteins derived from filamentous fungi that can be easily purified by a surfactant-based aqueous two-phase system. In this study, the hydrophobin HFBI sequence from Trichoderma reesei was fused to green fluorescent protein (GFP) and transiently expressed in Nicotiana benthamiana plants by Agrobacterium tumefaciens infiltration. The HFBI fusion significantly enhanced the accumulation of GFP, with the concentration of the fusion protein reaching 51% of total soluble protein, while also delaying necrosis of the infiltrated leaves. Furthermore, the endoplasmic reticulum-targeted GFP-HFBI fusion induced the formation of large novel protein bodies. A simple and scalable surfactant-based aqueous two-phase system was optimized to recover the HFBI fusion proteins from leaf extracts. The single-step phase separation was able to selectively recover up to 91% of the GFP-HFBI up to concentrations of 10 mg mL(-1). HFBI fusions increased the expression levels of plant-made recombinant proteins while also providing a simple means for their subsequent purification. This hydrophobin fusion technology, when combined with the speed and posttranslational modification capabilities of plants, enhances the value of transient plant-based expression systems.
Collapse
Affiliation(s)
- Jussi J Joensuu
- VTT Biotechnology, VTT Technical Research Centre of Finland, Espoo, 02044 VTT, Finland.
| | | | | | | | | | | |
Collapse
|
20
|
Abstract
Plant-derived biologicals for use in animal health are becoming an increasingly important target for research into alternative, improved methods for disease control. Although there are no commercial products on the market yet, the development and testing of oral, plant-based vaccines is now beyond the proof-of-principle stage. Vaccines, such as those developed for porcine transmissible gastroenteritis virus, have the potential to stimulate both mucosal and systemic, as well as, lactogenic immunity as has already been seen in target animal trials. Plants are a promising production system, but they must compete with existing vaccines and protein production platforms. In addition, regulatory hurdles will need to be overcome, and industry and public acceptance of the technology are important in establishing successful products.
Collapse
Affiliation(s)
- R W Hammond
- USDA-ARS, BARC-West, Rm.252, Bldg. 011, Beltsville, MD 20705, USA.
| | | |
Collapse
|
21
|
Tiwari S, Verma PC, Singh PK, Tuli R. Plants as bioreactors for the production of vaccine antigens. Biotechnol Adv 2009; 27:449-67. [PMID: 19356740 PMCID: PMC7126855 DOI: 10.1016/j.biotechadv.2009.03.006] [Citation(s) in RCA: 102] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2008] [Revised: 03/27/2009] [Accepted: 03/31/2009] [Indexed: 12/12/2022]
Abstract
Plants have been identified as promising expression systems for commercial production of vaccine antigens. In phase I clinical trials several plant-derived vaccine antigens have been found to be safe and induce sufficiently high immune response. Thus, transgenic plants, including edible plant parts are suggested as excellent alternatives for the production of vaccines and economic scale-up through cultivation. Improved understanding of plant molecular biology and consequent refinement in the genetic engineering techniques have led to designing approaches for high level expression of vaccine antigens in plants. During the last decade, several efficient plant-based expression systems have been examined and more than 100 recombinant proteins including plant-derived vaccine antigens have been expressed in different plant tissues. Estimates suggest that it may become possible to obtain antigen sufficient for vaccinating millions of individuals from one acre crop by expressing the antigen in seeds of an edible legume, like peanut or soybean. In the near future, a plethora of protein products, developed through ‘naturalized bioreactors’ may reach market. Efforts for further improvements in these technologies need to be directed mainly towards validation and applicability of plant-based standardized mucosal and edible vaccines, regulatory pharmacology, formulations and the development of commercially viable GLP protocols. This article reviews the current status of developments in the area of use of plants for the development of vaccine antigens.
Collapse
Affiliation(s)
| | | | | | - Rakesh Tuli
- Corresponding author. National Botanical Research Institute, Council of Scientific and Industrial Research, Rana Pratap Marg, Lucknow-226001 (U.P.) India. Tel.: +91 522 2205848; fax: +91 522 2205839.
| |
Collapse
|
22
|
Conley AJ, Mohib K, Jevnikar AM, Brandle JE. Plant recombinant erythropoietin attenuates inflammatory kidney cell injury. PLANT BIOTECHNOLOGY JOURNAL 2009; 7:183-99. [PMID: 19055608 DOI: 10.1111/j.1467-7652.2008.00389.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Human erythropoietin (EPO) is a pleiotropic cytokine with remarkable tissue-protective activities in addition to its well-established role in red blood cell production. Unfortunately, conventional mammalian cell cultures are unlikely to meet the anticipated market demands for recombinant EPO because of limited capacity and high production costs. Plant expression systems may address these limitations to enable practical, cost-effective delivery of EPO in tissue injury prevention therapeutics. In this study, we produced human EPO in tobacco and demonstrated that plant-derived EPO had tissue-protective activity. Our results indicated that targeting to the endoplasmic reticulum (ER) provided the highest accumulation levels of EPO, with a yield approaching 0.05% of total soluble protein in tobacco leaves. The codon optimization of the human EPO gene for plant expression had no clear advantage; furthermore, the human EPO signal peptide performed better than a tobacco signal peptide. In addition, we found that glycosylation was essential for the stability of plant recombinant EPO, whereas the presence of an elastin-like polypeptide fusion had a limited positive impact on the level of EPO accumulation. Confocal microscopy showed that apoplast and ER-targeted EPO were correctly localized, and N-glycan analysis demonstrated that complex plant glycans existed on apoplast-targeted EPO, but not on ER-targeted EPO. Importantly, plant-derived EPO had enhanced receptor-binding affinity and was able to protect kidney epithelial cells from cytokine-induced death in vitro. These findings demonstrate that tobacco plants may be an attractive alternative for the production of large amounts of biologically active EPO.
Collapse
Affiliation(s)
- Andrew J Conley
- Department of Biology, University of Western Ontario, London, ON, Canada, N6A 5B7
| | | | | | | |
Collapse
|
23
|
Escribano JM, Perez-Filgueira DM. Strategies for improving vaccine antigens expression in transgenic plants: fusion to carrier sequences. Methods Mol Biol 2009; 483:275-287. [PMID: 19183905 DOI: 10.1007/978-1-59745-407-0_16] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Transgenic plants are gaining increasing attention from the industry as a natural bioreactor for the production of industrial and chemical products. Optimization of transgene expression in plant cells holds the key to maximizing the potential of plants for producing proteins of commercial interest. This chapter is devoted to the description of the methods utilized for the generation of transgenic plants expressing a canine parvovirus vaccine peptide or virus-like particles from a rabbit calicivirus.
Collapse
|
24
|
Xiong N, Zhang Y, Wang Y, Yang BY, Chen SY. Isolation and identification of canine parvovirus serotype 2a and its VP2 protein expression in transgenic tobacco. Virol Sin 2008. [DOI: 10.1007/s12250-008-2928-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
25
|
Perea Arango I, Loza Rubio E, Rojas Anaya E, Olivera Flores T, Gonzalez de la Vara L, Gómez Lim MA. Expression of the rabies virus nucleoprotein in plants at high-levels and evaluation of immune responses in mice. PLANT CELL REPORTS 2008; 27:677-85. [PMID: 18270708 DOI: 10.1007/s00299-007-0324-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/03/2006] [Revised: 01/26/2007] [Accepted: 02/10/2007] [Indexed: 05/02/2023]
Abstract
Transgenic plants have been employed successfully as a low-cost system for the production of therapeutically valuable proteins including antibodies, antigens and hormones. Here, we report expression of a full-length nucleoprotein gene of rabies virus in transgenic tomato plants. The nucleoprotein was also transiently expressed in Nicotiana benthamiana plants by agroinfiltration. In both cases, the nucleoprotein was expressed at high levels, 1-5% of total soluble protein in tomato and 45% in N. benthamiana. Previously, only epitopes of the nucleoprotein had been expressed in plants. The presence and expression of the transgene was verified by PCR, Southern, northern and western blots. Mice were immunized both intraperitoneally (i.p.) and orally with tomato protein extracts containing the N protein induced the production of antibodies. The antibody titer of mice immunized i.p., was at least four times higher than that of mice immunized orally. These results were reflected in the challenge experiments where i.p.-immunized mice were partially protected against a peripheral virus challenge whereas orally immunized mice were not. This protection was comparable to that obtained in previous experiments employing different expression systems. Work is in progress to express both G and N proteins in transgenic plants and evaluate protection in mice.
Collapse
Affiliation(s)
- Irene Perea Arango
- Departamento de Ingeniería Genética de Plantas, Libramiento Norte Carretera Irapuato-León, Irapuato, 36500, Guanajuato, Mexico
| | | | | | | | | | | |
Collapse
|
26
|
Joensuu JJ, Niklander-Teeri V, Brandle JE. Transgenic plants for animal health: plant-made vaccine antigens for animal infectious disease control. PHYTOCHEMISTRY REVIEWS : PROCEEDINGS OF THE PHYTOCHEMICAL SOCIETY OF EUROPE 2008; 7:553-577. [PMID: 32214922 PMCID: PMC7089046 DOI: 10.1007/s11101-008-9088-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/09/2007] [Accepted: 02/05/2008] [Indexed: 05/19/2023]
Abstract
A variety of plant species have been genetically modified to accumulate vaccine antigens for human and animal health and the first vaccine candidates are approaching the market. The regulatory burden for animal vaccines is less than that for human use and this has attracted the attention of researchers and companies, and investment in plant-made vaccines for animal infectious disease control is increasing. The dosage cost of vaccines for animal infectious diseases must be kept to a minimum, especially for non-lethal diseases that diminish animal welfare and growth, so efficient and economic production, storage and delivery are critical for commercialization. It has become clear that transgenic plants are an economic and efficient alternative to fermentation for large-scale production of vaccine antigens. The oral delivery of plant-made vaccines is particularly attractive since the expensive purification step can be avoided further reducing the cost per dose. This review covers the current status of plant-produced vaccines for the prevention of disease in animals and focuses on barriers to the development of such products and methods to overcome them.
Collapse
Affiliation(s)
- J. J. Joensuu
- Department of Applied Biology, University of Helsinki, P.O. Box 27, 00014 Helsinki, Finland
- Southern Crop Protection and Food Research Centre, Agriculture and Agri-Food Canada, 1391 Sandford Street, London, ON Canada N5V 4T3
| | - V. Niklander-Teeri
- Department of Applied Biology, University of Helsinki, P.O. Box 27, 00014 Helsinki, Finland
| | - J. E. Brandle
- Southern Crop Protection and Food Research Centre, Agriculture and Agri-Food Canada, 1391 Sandford Street, London, ON Canada N5V 4T3
| |
Collapse
|
27
|
Expression, purification, and characterization of VP2 capsid protein of canine parvovirus in Escherichia coli. World J Microbiol Biotechnol 2007. [DOI: 10.1007/s11274-007-9493-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Park JS, Choi BK, Vijayachandran LS, Ayyappan V, Chong CK, Lee KS, Kim SC, Choi CW. Immunodetection of Canine Parvovirus (CPV) in clinical samples by polyclonal antisera against CPV-VP2 protein expressed in Esherichia coli as an antigen. J Virol Methods 2007; 146:281-7. [PMID: 17825928 DOI: 10.1016/j.jviromet.2007.07.021] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2006] [Revised: 05/23/2007] [Accepted: 07/16/2007] [Indexed: 10/22/2022]
Abstract
The entire virion protein 2 (VP2) gene of Canine Parvovirus (CPV) was amplified by polymerase chain reaction (PCR) and engineered to be expressed by a bacterial expression vector pET-28a, under the control of the IPTG-inducible T7lac promoter. SDS-PAGE gel revealed that VP2 expressed as a 67kDa, and found mainly in the pellet of the bacterial lysates, suggesting that cytoplasmic expression is not preferred. The recombinant protein VP2 fused with His-tag was purified from Esherichia coli using Ni-NTA resin under denaturing conditions. SDS-PAGE analysis also showed the high expression of several lower molecular weight (LMW) bands. Western blot analysis showed that polyclonal antisera produced by rabbit against E. coli-VP2 protein reacted specifically with the purified VP2 protein as well as two other LMW bands. Some of the resulting LMW products failed to keep their antigenic site in the N-terminal region of the VP2. The degradation of recombinant VP2 protein in E. coli could be due to the action of host proteases. The immunodetection ability of the polyclonal antisera was compared with that of a commercial monoclonal antibody to test numerous clinical specimens by immuno-dot blot assays. There were distinctive differences in the degree of immunodetection ability of polyclonal antisera and monoclonal antibody to react with CPV antigens. The reaction time of polyclonal antisera was much faster in visual color appearance than that of monoclonal antibody during NBT/BCIP staining. The result from diagnostic PCR assay confirmed the presence of CPV in 44 out of 46 specimens collected, consistent with polyclonal antisera-positive result. Therefore, the polyclonal antisera can be used for CPV detection in the faeces of diarrhoeic dogs, which was found to be more rapid, sensitive, broad but less specific than the monoclonal antibody.
Collapse
Affiliation(s)
- Jae Sung Park
- Department of Biology & Medicinal Science, Pai Chai University, Daejeon 302-735, Republic of Korea
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Wu J, Yu L, Li L, Hu J, Zhou J, Zhou X. Oral immunization with transgenic rice seeds expressing VP2 protein of infectious bursal disease virus induces protective immune responses in chickens. PLANT BIOTECHNOLOGY JOURNAL 2007; 5:570-8. [PMID: 17561926 DOI: 10.1111/j.1467-7652.2007.00270.x] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
The expression of infectious bursal disease virus (IBDV) host-protective immunogen VP2 protein in rice seeds, its immunogenicity and protective capability in chickens were investigated. The VP2 cDNA of IBDV strain ZJ2000 was cloned downstream of the Gt1 promoter of the rice glutelin GluA-2 gene in the binary expression vector, pCambia1301-Gt1. Agrobacterium tumefaciens containing the recombinant vector was used to transform rice embryogenic calli, and 121 transgenic lines were obtained and grown to maturity in a greenhouse. The expression level of VP2 protein in transgenic rice seeds varied from 0.678% to 4.521% microg/mg of the total soluble seed protein. Specific pathogen-free chickens orally vaccinated with transgenic rice seeds expressing VP2 protein produced neutralizing antibodies against IBDV and were protected when challenged with a highly virulent IBDV strain, BC6/85. These results demonstrate that transgenic rice seeds expressing IBDV VP2 can be used as an effective, safe and inexpensive vaccine against IBDV.
Collapse
Affiliation(s)
- Jianxiang Wu
- State Key Laboratory of Rice Biology, Institute of Biotechnology, Zhejiang University, Hangzhou 31009, China
| | | | | | | | | | | |
Collapse
|
30
|
Floss DM, Falkenburg D, Conrad U. Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: an overview. Transgenic Res 2007; 16:315-32. [PMID: 17436059 PMCID: PMC7089296 DOI: 10.1007/s11248-007-9095-x] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2007] [Accepted: 03/19/2007] [Indexed: 11/29/2022]
Abstract
During the past two decades, antibodies, antibody derivatives and vaccines have been developed for therapeutic and diagnostic applications in human and veterinary medicine. Numerous species of dicot and monocot plants have been genetically modified to produce antibodies or vaccines, and a number of diverse transformation methods and strategies to enhance the accumulation of the pharmaceutical proteins are now available. Veterinary applications are the specific focus of this article, in particular for pathogenic viruses, bacteria and eukaryotic parasites. We focus on the advantages and remaining challenges of plant-based therapeutic proteins for veterinary applications with emphasis on expression platforms, technologies and economic considerations.
Collapse
Affiliation(s)
- Doreen Manuela Floss
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstrasse 3, Gatersleben, 06466 Germany
| | | | - Udo Conrad
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstrasse 3, Gatersleben, 06466 Germany
| |
Collapse
|
31
|
Kamarajugadda S, Daniell H. Chloroplast-derived anthrax and other vaccine antigens: their immunogenic and immunoprotective properties. Expert Rev Vaccines 2007; 5:839-49. [PMID: 17184221 DOI: 10.1586/14760584.5.6.839] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Transgenic plants offer many advantages, including low cost of production (by elimination of fermenters), storage and transportation, heat stability, absence of human pathogens, protection of antigens in the stomach through bioencapsulation (when delivered orally), elimination of the need for expensive purification and sterile injections and generation of both systemic and mucosal immunity. Recent studies have demonstrated that chloroplast-derived anthrax-protective antigen elicits effective immune responses, develops neutralizing antibodies, confers complete protection against anthrax lethal toxin challenge and produces 360 million doses of vaccine in one acre of transgenic plants. Chloroplast-derived vaccine antigens are efficacious against bacterial, fungal, viral and protozoan pathogens.
Collapse
Affiliation(s)
- Sushama Kamarajugadda
- Department of Molecular Biology and Microbiology, University of Central Florida, Bimolecular science Building 20, room 336, Orlando, FL 32816-2364, USA
| | | |
Collapse
|
32
|
Sels J, Delauré SL, Aerts AM, Proost P, Cammue BPA, De Bolle MFC. Use of a PTGS-MAR expression system for efficient in planta production of bioactive Arabidopsis thaliana plant defensins. Transgenic Res 2006; 16:531-8. [PMID: 17180735 DOI: 10.1007/s11248-006-9057-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2006] [Accepted: 11/15/2006] [Indexed: 10/23/2022]
Abstract
Plant defensins, exhibiting various levels of inhibitory activity against fungal pathogens, are potent candidates for pharmaceutical or agricultural antimycotics. Study of the plant defensins from the model plant Arabidopsis thaliana requires the purification of these peptides. However, heterologous production of defensins for large-scale in vitro bioactivity assays is often experienced as a major problem. In this study we describe the transgenic expression of a previously identified seed-specific and a so far uncharacterized plant defensin gene in their host A. thaliana using a formerly developed plant expression system. Therefore, both genes were cloned in a matrix attachment region (MAR) based plant transformation vector and expressed in post-transcriptional gene silencing (PTGS) impaired A. thaliana plants. The peptides were purified to homogeneity and were correctly processed, as confirmed by mass spectrometry analysis. Finally, they were assessed for their in vitro antifungal activity and mode of antifungal action. Our results indicate that the PTGS-MAR expression system can be applied to obtain significant amounts of bioactive, rightly processed plant peptides from leaves of first generation transgenic plants.
Collapse
Affiliation(s)
- Jan Sels
- Centre of Microbial and Plant Genetics, Katholieke Universiteit Leuven, Kasteelpark Arenberg 20, Heverlee, Belgium
| | | | | | | | | | | |
Collapse
|
33
|
Ledesma A, Moral V, Villalba M, Salinas J, Rodríguez R. Ca2+-binding allergens from olive pollen exhibit biochemical and immunological activity when expressed in stable transgenic Arabidopsis. FEBS J 2006; 273:4425-34. [PMID: 16956374 DOI: 10.1111/j.1742-4658.2006.05417.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Employing transgenic plants as alternative systems to the conventional Escherichia coli, Pichia pastoris or baculovirus hosts to produce recombinant allergens may offer the possibility of having available edible vaccines in the near future. In this study, two EF-hand-type Ca2+-binding allergens from olive pollen, Ole e 3 and Ole e 8, were produced in transgenic Arabidopsis thaliana plants. The corresponding cDNAs, under the control of the constitutive CaMV 35S promoter, were stably incorporated into the Arabidopsis genome and encoded recombinant proteins, AtOle e 3 and AtOle e 8, which exhibited the molecular properties (i.e. MS analyses and CD spectra) of their olive and/or E. coli counterparts. Calcium-binding assays, which were carried out to assess the biochemical activity of AtOle e 3 and AtOle e 8, gave positive results. In addition, their mobilities on SDS/PAGE were according to the conformational changes derived from their Ca2+-binding capability. The immunological behaviour of Arabidopsis-expressed proteins was equivalent to that of the natural- and/or E. coli-derived allergens, as shown by their ability to bind allergen-specific rabbit IgG antiserum and IgE from sensitized patients. These results indicate that transgenic plants constitute a valid alternative to obtain allergens with structural and immunological integrity not only for scaling up production, but also to develop new kind of vaccines for human utilization.
Collapse
Affiliation(s)
- Amalia Ledesma
- Dpto. Bioquímica y Biología Molecular I, Universidad Complutense, Madrid, Spain
| | | | | | | | | |
Collapse
|
34
|
Twyman RM, Schillberg S, Fischer R. Transgenic plants in the biopharmaceutical market. Expert Opin Emerg Drugs 2006; 10:185-218. [PMID: 15757412 DOI: 10.1517/14728214.10.1.185] [Citation(s) in RCA: 96] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Many of our 'small-molecule-drugs' are natural products from plants, or are synthetic compounds based on molecules found naturally in plants. However, the vast majority of the protein therapeutics (or biopharmaceuticals) we use are from animal or human sources, and are produced commercially in microbial or mammalian bioreactor systems. Over the last few years, it has become clear that plants have great potential for the production of human proteins and other protein-based therapeutic entities. Plants offer the prospect of inexpensive biopharmaceutical production without sacrificing product quality or safety, and following the success of several plant-derived technical proteins, the first therapeutic products are now approaching the market. In this review, the different plant-based production systems are discussed and the merits of transgenic plants are evaluated compared with other platforms. A detailed discussion is provided of the development issues that remain to be addressed before plants become an acceptable mainstream production technology. The many different proteins that have already been produced using plants are described, and a sketch of the current market and the activities of the key players is provided. Despite the currently unclear regulatory framework and general industry inertia, the benefits of plant-derived pharmaceuticals are now bringing the prospect of inexpensive veterinary and human medicines closer than ever before.
Collapse
Affiliation(s)
- Richard M Twyman
- University of York, Department of Biology, Heslington, York, YO10 5DD, UK.
| | | | | |
Collapse
|
35
|
Obregon P, Chargelegue D, Drake PMW, Prada A, Nuttall J, Frigerio L, Ma JKC. HIV-1 p24-immunoglobulin fusion molecule: a new strategy for plant-based protein production. PLANT BIOTECHNOLOGY JOURNAL 2006; 4:195-207. [PMID: 17177796 DOI: 10.1111/j.1467-7652.2005.00171.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
We describe the engineering of a human immunodeficiency virus-1 (HIV-1) p24-immunoglobulin A (IgA) antigen-antibody fusion molecule for therapeutic purposes and its enhancing effect on fused antigen expression in tobacco plants. Although many recombinant proteins have been expressed in transgenic plants as vaccine candidates, low levels of expression are a recurring problem. In this paper, using the HIV p24 core antigen as a model vaccine target, we describe a strategy for increasing the yield of a recombinant protein in plants. HIV p24 antigen was expressed as a genetic fusion with the alpha2 and alpha3 constant region sequences from human Ig alpha-chain and targeted to the endomembrane system. The expression of this fusion protein was detected at levels approximately 13-fold higher than HIV p24 expressed alone, and a difference in the behaviour of the two recombinant proteins during trafficking in the plant secretory pathway has been identified. Expressing the antigen within the context of alpha-chain Ig sequences resulted in the formation of homodimers and the antigen was correctly recognized by specific antibodies. Furthermore, the HIV p24 elicited T-cell and antibody responses in immunized mice. The use of Ig fusion partners is proposed as a generic platform technology for up-regulating the expression of antigens in plants, and may represent the first step in a strategy to design new vaccines with enhanced immunological properties.
Collapse
Affiliation(s)
- Patricia Obregon
- Department of Cellular and Molecular Medicine, Infectious Diseases, Immunology Unit, St. George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK.
| | | | | | | | | | | | | |
Collapse
|
36
|
Gil F, Titarenko E, Terrada E, Arcalís E, Escribano JM. Successful oral prime-immunization with VP60 from rabbit haemorrhagic disease virus produced in transgenic plants using different fusion strategies. PLANT BIOTECHNOLOGY JOURNAL 2006; 4:135-43. [PMID: 17177792 DOI: 10.1111/j.1467-7652.2005.00172.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Expression levels of vaccine antigens in transgenic plants have important consequences in their use as edible vaccines. The major structural protein VP60 from the rabbit haemorrhagic disease virus (RHDV) has been produced in transgenic plants using different strategies to compare its accumulation in plant tissues. The highest expressing plants were those presenting stable, complex, high-density structures formed by VP60, suggesting the importance of multisubunit structures for the stability of this protein in plant cells. Mice fed with leaves of transgenic plants expressing VP60 were primed to a subimmunogenic baculovirus-derived vaccine single dose. This indicates that plants expressing VP60 antigen may be a new means for oral RHDV immunization.
Collapse
Affiliation(s)
- Félix Gil
- Departamento de Biotecnología, INIA, Carretera de la Coruña Km7, 28040 Madrid, Spain
| | | | | | | | | |
Collapse
|
37
|
Molina A, Veramendi J, Hervás-Stubbs S. Induction of neutralizing antibodies by a tobacco chloroplast-derived vaccine based on a B cell epitope from canine parvovirus. Virology 2005; 342:266-75. [PMID: 16140352 DOI: 10.1016/j.virol.2005.08.009] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2005] [Revised: 07/14/2005] [Accepted: 08/09/2005] [Indexed: 10/25/2022]
Abstract
The 2L21 epitope of the VP2 protein from the canine parvovirus (CPV), fused to the cholera toxin B subunit (CTB-2L21), was expressed in transgenic tobacco chloroplasts. Mice and rabbits that received protein-enriched leaf extracts by parenteral route produced high titers of anti-2L21 antibodies able to recognize the VP2 protein. Rabbit sera were able to neutralize CPV in an in vitro infection assay with an efficacy similar to the anti-2L21 neutralizing monoclonal antibody 3C9. Anti-2L21 IgG and seric IgA antibodies were elicited when mice were gavaged with a suspension of pulverized tissues from CTB-2L21 transformed plants. Combined immunization (a single parenteral injection followed by oral boosters) shows that oral boosters help to maintain the anti-2L21 IgG response induced after a single injection, whereas parenteral administration of the antigen primes the subsequent oral boosters by promoting the induction of anti-2L21 seric IgA antibodies. Despite the induced humoral response, antibodies elicited by oral delivery did not show neutralizing capacity in the in vitro assay. The high yield of the fusion protein permits the preparation of a high number of vaccine doses from a single plant and makes feasible the oral vaccination using a small amount of crude plant material. However, a big effort has still to be done to enhance the protective efficacy of subunit vaccines by the oral route.
Collapse
MESH Headings
- Administration, Oral
- Animals
- Antibodies, Viral/blood
- Capsid Proteins/genetics
- Capsid Proteins/immunology
- Chloroplasts/genetics
- Cholera Toxin/immunology
- Cholera Toxin/metabolism
- Epitopes, B-Lymphocyte/genetics
- Epitopes, B-Lymphocyte/immunology
- Female
- Humans
- Immunization, Secondary
- Immunoglobulin A/analysis
- Immunoglobulin G/analysis
- Injections, Intradermal
- Injections, Intraperitoneal
- Mice
- Mice, Inbred BALB C
- Neutralization Tests
- Parvoviridae Infections/blood
- Parvoviridae Infections/immunology
- Parvovirus, Canine/chemistry
- Parvovirus, Canine/immunology
- Plant Extracts
- Plants, Genetically Modified
- Rabbits
- Nicotiana/genetics
- Vaccination
- Vaccines, Synthetic/administration & dosage
- Viral Vaccines/administration & dosage
Collapse
Affiliation(s)
- Andrea Molina
- Instituto de Agrobiotecnología, Universidad Pública de Navarra-CSIC, Campus Arrosadía, 31006 Pamplona, Spain
| | | | | |
Collapse
|
38
|
Abstract
The expression of antigens in transgenic plants has been increasingly used in the development of experimental vaccines, particularly oriented to the development of edible vaccines. Hence, this technology becomes highly suitable to express immunogenic proteins from pathogens. Foot and mouth disease virus, bovine rotavirus and bovine viral diarrhoea virus are considered to be the most important causative agents of economic loss of cattle production in Argentina, and they are thus optimal candidates for alternative means of immunization. Here, we present a review of our results corresponding to the expression of immunogenic proteins from these three viruses in alfalfa transgenic plants, and we discuss the possibility of using them for the development of plant-based vaccines.
Collapse
MESH Headings
- Animals
- Antigens, Viral/genetics
- Antigens, Viral/immunology
- Arabidopsis/genetics
- Arabidopsis/metabolism
- Cattle
- Cattle Diseases/immunology
- Cattle Diseases/prevention & control
- Cattle Diseases/virology
- Diarrhea Viruses, Bovine Viral/genetics
- Diarrhea Viruses, Bovine Viral/immunology
- Foot-and-Mouth Disease Virus/genetics
- Foot-and-Mouth Disease Virus/immunology
- Medicago sativa/genetics
- Medicago sativa/metabolism
- Plants, Genetically Modified/genetics
- Plants, Genetically Modified/metabolism
- Rotavirus/genetics
- Rotavirus/immunology
- Solanum tuberosum/genetics
- Solanum tuberosum/metabolism
- Vaccines, Edible/administration & dosage
- Vaccines, Edible/biosynthesis
- Vaccines, Edible/genetics
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/biosynthesis
- Vaccines, Synthetic/genetics
- Veterinary Medicine/methods
- Viral Proteins/genetics
- Viral Proteins/immunology
- Viral Vaccines/administration & dosage
- Viral Vaccines/biosynthesis
- Viral Vaccines/genetics
Collapse
|
39
|
Abstract
Transgenic plant-derived vaccines offer a new strategy for the development of safe, inexpensive vaccines against diarrhoeal diseases. In animal and Phase I clinical studies, these vaccines have been safe and immunogenic without the need for a buffer or vehicle other than the plant cell. This review examines some early attempts to develop oral transgenic plant vaccines against enteric infections such as enterotoxigenic Escherichia coli infection, cholera and norovirus infection.
Collapse
Affiliation(s)
- Carol O Tacket
- Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21202, USA.
| |
Collapse
|
40
|
Smahel M, Pokorná D, Macková J, Vlasák J. Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase. J Gene Med 2005; 6:1092-101. [PMID: 15386741 DOI: 10.1002/jgm.596] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND Human papillomavirus type 16 (HPV16) E7 is an unstable oncoprotein with low immunogenicity. In previous work, we prepared the E7GGG gene containing point mutations resulting in substitution of three amino acids in the pRb-binding site of the HPV16 E7 protein. METHODS AND RESULTS To increase E7GGG immunogenicity we constructed fusion genes of E. coli beta-glucuronidase (GUS) with one or three copies of E7GGG. Furthermore, a similar construct was prepared with partial E7GGG (E7GGGp, 41 amino acids from the N-terminus). The expression of the fusion genes was examined in human 293T cells. Quantification of GUS activity and the amount of E7 antigen showed substantially reduced GUS activity of fusion proteins with complete E7GGG that was mainly caused by decrease of their steady-state level in comparison with GUS or E7GGGpGUS. Still, the steady-state level of E7GGG.GUS was about 20-fold higher than that of the E7GGG protein. The immunogenicity of the fusion genes with complete E7GGG was tested by DNA immunisation of C57BL/6 mice with a gene gun. TC-1 cells and their clone TC-1/A9 with down-regulated MHC class I expression were subcutaneously (s.c.) inoculated to induce tumour formation. All mice were protected against challenge with TC-1 cells and most animals remained tumour-free in therapeutic-immunisation experiments with these cells, in contrast to immunisation with unfused E7GGG and the fusion with the lysosome-associated membrane protein 1 (Sig/E7GGG/LAMP-1). Significant protection was also recorded against TC-1/A9 cells. Both tetramer staining and ELISPOT assay showed substantially higher activation of E7-specific CD8+ lymphocytes in comparison with E7GGG and Sig/E7GGG/LAMP-1. Deletion of 231 bp in the GUS gene eliminated enzymatic activity, but did not influence the immunogenicity of the E7GGG.GUS gene. CONCLUSIONS The findings demonstrate the superior immunisation efficacy of the fusion genes of E7GGG with GUS when compared with E7GGG and Sig/E7GGG/LAMP-1. The E7GGG.GUS-based DNA vaccine might also be efficient against human tumour cells with reduced MHC class I expression.
Collapse
Affiliation(s)
- Michal Smahel
- Institute of Hematology and Blood Transfusion, Department of Experimental Virology, Prague, Czech Republic.
| | | | | | | |
Collapse
|
41
|
Wigdorovitz A, Mozgovoj M, Santos MJD, Parreño V, Gómez C, Pérez-Filgueira DM, Trono KG, Ríos RD, Franzone PM, Fernández F, Carrillo C, Babiuk LA, Escribano JM, Borca MV. Protective lactogenic immunity conferred by an edible peptide vaccine to bovine rotavirus produced in transgenic plants. J Gen Virol 2004; 85:1825-1832. [PMID: 15218166 DOI: 10.1099/vir.0.19659-0] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Vaccines produced in transgenic plants constitute a promising alternative to conventional immunogens, presenting the possibility of stimulating secretory and systemic immunity against enteric pathogens when administered orally. Protection against enteric pathogens affecting newborn animals requires, in most cases, the stimulation of lactogenic immunity. Here, the group presents the development of an experimental immunogen based on expression of an immunorelevant peptide, eBRV4, of the VP4 protein of bovine rotavirus (BRV), which has been described as harbouring at least one neutralizing epitope as well as being responsible for the adsorption of the virus to epithelial cells. The eBRV4 epitope was efficiently expressed in transgenic alfalfa as a translational fusion protein with the highly stable reporter enzyme β-glucuronidase (βGUS), which served as a carrier, stabilized the synthesized peptide and facilitated screening for the higher expression levels in plants. Correlation of expression of the eBRV4 epitope in plants with those presenting the highest βGUS activities was confirmed by a Western blot assay specific for the BRV peptide. The eBRV4 epitope expressed in plants was effective in inducing an anti-rotavirus antibody response in adult female mice when administered either intraperitoneally or orally and, more importantly, suckling mice born from immunized female mice were protected against oral challenge with virulent rotavirus. These results demonstrate the feasibility of inducing lactogenic immunity against an enteric pathogen using an edible vaccine produced in transgenic plants.
Collapse
Affiliation(s)
- Andrés Wigdorovitz
- Consejo Nacional e Investigaciones Científicas y Técnicas (CONICET), Argentina
- Instituto de Virología, CICV, INTA-Castelar, CC77, Morón 1708, Buenos Aires, Argentina
| | - Marina Mozgovoj
- Instituto de Virología, CICV, INTA-Castelar, CC77, Morón 1708, Buenos Aires, Argentina
| | - María J Dus Santos
- Instituto de Virología, CICV, INTA-Castelar, CC77, Morón 1708, Buenos Aires, Argentina
| | - Viviana Parreño
- Instituto de Virología, CICV, INTA-Castelar, CC77, Morón 1708, Buenos Aires, Argentina
| | - Cristina Gómez
- Instituto de Genética 'E. A. Favret', CICA, INTA-Castelar, Buenos Aires, Argentina
| | - Daniel M Pérez-Filgueira
- Departamento de Biotecnología and Centro de Investigación en Sanidad Animal, INIA, Valdeolmos, 28140 Madrid, Spain
- Consejo Nacional e Investigaciones Científicas y Técnicas (CONICET), Argentina
| | - Karina G Trono
- Instituto de Virología, CICV, INTA-Castelar, CC77, Morón 1708, Buenos Aires, Argentina
| | - Raúl D Ríos
- Instituto de Genética 'E. A. Favret', CICA, INTA-Castelar, Buenos Aires, Argentina
| | - Pascual M Franzone
- Instituto de Genética 'E. A. Favret', CICA, INTA-Castelar, Buenos Aires, Argentina
| | - Fernando Fernández
- Instituto de Virología, CICV, INTA-Castelar, CC77, Morón 1708, Buenos Aires, Argentina
| | - Consuelo Carrillo
- Instituto de Virología, CICV, INTA-Castelar, CC77, Morón 1708, Buenos Aires, Argentina
| | - Lorne A Babiuk
- University of Saskatchewan, VIDO, Saskatoon, SK, Canada, S7N 5E3
| | - José M Escribano
- Departamento de Biotecnología and Centro de Investigación en Sanidad Animal, INIA, Valdeolmos, 28140 Madrid, Spain
| | - Manuel V Borca
- Consejo Nacional e Investigaciones Científicas y Técnicas (CONICET), Argentina
- Instituto de Virología, CICV, INTA-Castelar, CC77, Morón 1708, Buenos Aires, Argentina
| |
Collapse
|
42
|
Molina A, Hervás-Stubbs S, Daniell H, Mingo-Castel AM, Veramendi J. High-yield expression of a viral peptide animal vaccine in transgenic tobacco chloroplasts. PLANT BIOTECHNOLOGY JOURNAL 2004; 2:141-53. [PMID: 17147606 DOI: 10.1046/j.1467-7652.2004.00057.x] [Citation(s) in RCA: 106] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
The 2L21 peptide, which confers protection to dogs against challenge with virulent canine parvovirus (CPV), was expressed in tobacco chloroplasts as a C-terminal translational fusion with the cholera toxin B subunit (CTB) or the green fluorescent protein (GFP). Expression of recombinant proteins was dependent on plant age. A very high-yield production was achieved in mature plants at the time of full flowering (310 mg CTB-2L21 protein per plant). Both young and senescent plants accumulated lower amounts of recombinant proteins than mature plants. This shows the importance of the time of harvest when scaling up the process. The maximum level of CTB-2L21 was 7.49 mg/g fresh weight (equivalent to 31.1% of total soluble protein, TSP) and that of GFP-2L21 was 5.96 mg/g fresh weight (equivalent to 22.6% of TSP). The 2L21 inserted epitope could be detected with a CPV-neutralizing monoclonal antibody, indicating that the epitope is correctly presented at the C-terminus of the fusion proteins. The resulting chimera CTB-2L21 protein retained pentamerization and G(M1)-ganglioside binding characteristics of the native CTB and induced antibodies able to recognize VP2 protein from CPV. To our knowledge, this is the first report of an animal vaccine epitope expression in transgenic chloroplasts. The high expression of antigens in chloroplasts would reduce the amount of plant material required for vaccination (approximately 100 mg for a dose of 500 microg antigen) and would permit encapsulation of freeze-dried material or pill formation.
Collapse
Affiliation(s)
- Andrea Molina
- Instituto de Agrobiotecnología y Recursos Naturales, Universidad Pública de Navarra-CSIC, Campus Arrosadía, 31006 Pamplona, Spain
| | | | | | | | | |
Collapse
|
43
|
Teli NP, Timko MP. Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals. PLANT CELL, TISSUE AND ORGAN CULTURE 2004; 79:125-145. [PMID: 32214567 PMCID: PMC7089434 DOI: 10.1007/s11240-004-0653-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
In recent years there has been a dramatic increase in the application of plant biotechnology for the production of a variety of commercially valuable simple and complex biological molecules (biologics) for use in human and animal healthcare. Transgenic whole plants and plant cell culture systems have been developed that have the capacity to economically produce large-scale quantities of antibodies and antibody fragments, antigens and/or vaccine epitopes, metabolic enzymes, hormones, (neuro)peptides and a variety of biologically active complexes and secondary metabolites for direct use as therapeutic agents or diagnostic tools in the medical healthcare industry. As the products of genetically modified plants make their way from concept to commercialization the associated risks and acceptance by the public has been become a focal point. In this paper, we summarize the recent advances made in the use of transgenic plants and plant cell cultures as biological factories for the production of human therapeutics and biopharmaceuticals and discuss the long-term potential of `molecular farming' as a low-cost, efficient method for the production of biological materials with demonstrated utility to the pharmaceutical industry or medical community.
Collapse
Affiliation(s)
- Nilesh P Teli
- Department of Biology, University of Virginia, Gilmer Hall 044, VA USA
| | - Michael P Timko
- Department of Biology, University of Virginia, Gilmer Hall 044, VA USA
| |
Collapse
|
44
|
Mackenzie JS, Field HE, Guyatt KJ. Managing emerging diseases borne by fruit bats (flying foxes), with particular reference to henipaviruses and Australian bat lyssavirus. J Appl Microbiol 2003; 94 Suppl:59S-69S. [PMID: 12675937 DOI: 10.1046/j.1365-2672.94.s1.7.x] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Since 1994, a number of novel viruses have been described from bats in Australia and Malaysia, particularly from fruit bats belonging to the genus Pteropus (flying foxes), and it is probable that related viruses will be found in other countries across the geographical range of other members of the genus. These viruses include Hendra and Nipah viruses, members of a new genus, Henipaviruses, within the family Paramyxoviridae; Menangle and Tioman viruses, new members of the Rubulavirus genus within the Paramyxoviridae; and Australian bat lyssavirus (ABLV), a member of the Lyssavirus genus in the family Rhabdoviridae. All but Tioman virus are known to be associated with human and/or livestock diseases. The isolation, disease associations and biological properties of the viruses are described, and are used as the basis for developing management strategies for disease prevention or control. These strategies are directed largely at disease minimization through good farm management practices, reducing the potential for exposure to flying foxes, and better disease recognition and diagnosis, and for ABLV specifically, the use of rabies vaccine for pre- and post-exposure prophylaxis. Finally, an intriguing and long-term strategy is that of wildlife immunization through plant-derived vaccination.
Collapse
Affiliation(s)
- J S Mackenzie
- Department of Microbiology and Parasitology, School of Molecular and Microbial Sciences, University of Queensland, Brisbane, Queensland, Australia.
| | | | | |
Collapse
|
45
|
Zhou JY, Wu JX, Cheng LQ, Zheng XJ, Gong H, Shang SB, Zhou EM. Expression of immunogenic S1 glycoprotein of infectious bronchitis virus in transgenic potatoes. J Virol 2003; 77:9090-3. [PMID: 12885926 PMCID: PMC167223 DOI: 10.1128/jvi.77.16.9090-9093.2003] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The expression of infectious bronchitis virus (IBV) S1 glycoprotein in potatoes and its immunogenicity in mice and chickens were investigated. Potato plants were genetically transformed with a cDNA construct encoding the IBV S1 glycoprotein with the Agrobacterium system. Genomic DNA and mRNA analyses of the transformed plantlets confirmed the integration of the foreign cDNA into the potato genome, as well as its transcription. Mice and chickens vaccinated with the expressed IBV S1 glycoprotein produced antibodies that neutralized IBV infectivity. After three immunizations, vaccinated chickens were completely protected from virulent IBV infection. These results demonstrate that transgenic potatoes expressing IBV S1 glycoprotein can be used as a source of recombinant antigen for vaccine production.
Collapse
Affiliation(s)
- Ji-Yong Zhou
- Institute of Preventive Veterinary Medicine, Zhejiang University, Hangzhou 310029, China
| | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
Plant systems are reviewed with regard to their ability to express and produce subunit vaccines. Examples of different types of expression systems producing a variety of vaccine candidates are illustrated. Many of these subunit vaccines have been purified and shown to elicit an immune response when injected into animal models. This review also includes vaccines that have been administered orally in a non-purified form as a food or feed product. Cases are highlighted which demonstrate that orally delivered plant-based vaccines can elicit immune responses and in some case studies, confer protection. Examples are used to illustrate some of the inherent advantages of a plant-based system, such as cost, ease of scale-up and convenience of delivery. Also, some of the key steps are identified that will be necessary to bring these new vaccines to the market.
Collapse
|
47
|
Abstract
Many advances continue to be made in the field of plant-derived vaccines. Plants have been shown capable of expressing a multicomponent vaccine that when orally delivered induces a T-helper cell subset 1 response and enables passive immunization. Furthermore, a plant-derived vaccine has been shown to protect against challenge in the target host. Increased antigen expression levels (up to 4.1% total soluble protein) have been obtained through transformation of the chloroplast genome. In view of these findings, plant-derived vaccines have been proved as valuable commodities to the world's health system; however, before their application, studies need to focus on optimization of immunization strategies and to investigate antigen stability.
Collapse
Key Words
- ctb, cholera toxin b subunit
- etec, enterotoxigenic escherichia coli
- fda, food and drug administration
- fmdv, foot and mouth disease virus
- hbsag, hepatitis b surface antigen
- ltb, heat-labile toxin of etec b subunit
- mv, measles virus
- tgev, transmissible gastroenteritis coronavirus
- tmv, tobacco mosaic virus
- tsp, total soluble protein
Collapse
MESH Headings
- Administration, Oral
- Animals
- Bacterial Vaccines
- Drug Stability
- Gene Expression Regulation, Plant
- Genetic Engineering/methods
- Humans
- Immunity, Mucosal/immunology
- Plants, Genetically Modified/genetics
- Plants, Genetically Modified/immunology
- Plants, Genetically Modified/virology
- Recombinant Fusion Proteins/administration & dosage
- Recombinant Fusion Proteins/biosynthesis
- Recombinant Fusion Proteins/genetics
- Recombinant Fusion Proteins/immunology
- Transformation, Genetic
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/biosynthesis
- Vaccines, Synthetic/genetics
- Viral Vaccines
Collapse
|
48
|
Vieira da Silva J, Garcia AB, Vieira Flores VMQ, Sousa de Macedo Z, Medina-Acosta E. Phytosecretion of enteropathogenic Escherichia coli pilin subunit A in transgenic tobacco and its suitability for early life vaccinology. Vaccine 2002; 20:2091-101. [PMID: 11972978 DOI: 10.1016/s0264-410x(02)00057-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
A plant expression cassette system was engineered to efficiently target proteins to the default secretory pathway, allowing the expression of DNA inserts in three frames as fusion proteins containing a synthetic tobacco calreticulin cleavable signal peptide sequence, with the advantage of producing the recombinant proteins by phytosecretion. As one approach to develop a vaccine to enteropathogenic Escherichia coli (EPEC) infection, the oral immunogenicity of phytosecreted BfpA, the structural subunit A of the bundle-forming pilus, expressed at high levels (7.7% of soluble protein) in transgenic tobacco tissues, was demonstrated in BALB/c mice by the induction and detection of fecal anti-BfpA antibodies.
Collapse
Affiliation(s)
- Jeferson Vieira da Silva
- Plant Biotechnology Section, Laboratory of Biotechnology, Center for Biosciences and Biotechnology, Universidade Estadual do Norte Fluminense, Avenida Alberto Lamego 2000, Horto, Campos dos Goytacazes, RJ CEP 28015-620, Brazil
| | | | | | | | | |
Collapse
|
49
|
Korban SS. Targeting and expression of antigenic proteins in transgenic plants for production of edible oral vaccines. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY. PLANT : JOURNAL OF THE TISSUE CULTURE ASSOCIATION 2002; 38:231-236. [PMID: 32214771 PMCID: PMC7088994 DOI: 10.1079/ivp2002292] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Exploiting plants as biological bioreactors for production and delivery of edible oral subunit vaccines is a promising application of biotechnology. Efforts to enhance expression levels of transgenes coding for antigenic proteins by exploiting promoters, targeting sequences, and enhancer elements have produced rather low quantities of the antigen in plant tissues, but enough to induce immune responses in feeding studies. This review will cover components of various gene constructs used in developing plant-based vaccines against a myriad of viral and bacterial diseases. Specifically, it will focus on sequences that are involved in targeting the antigen to mucosal tissues of the intestinal tract, thus enhancing the immunogenicity of the plant-based vaccine as well as those components that result in higher accumulation of the protein within the plant.
Collapse
Affiliation(s)
- Schuyler S. Korban
- Department of Natural Resources & Enrionmental Sciences, 310 ERML, University of Illinois, 61801 Urbana, IL
| |
Collapse
|
50
|
Abstract
The requirement for large quantities of therapeutic proteins has fueled interest in the production of recombinant proteins in plants and animals. The first commercial products to be made in this way have experienced much success, and it is predicted that in the future a plethora of protein products will be made using these 'natural' bioreactors.
Collapse
Affiliation(s)
- J W Larrick
- Planet Biotechnology, Inc., 2438 Wyandotte Street, Mountain View, CA 94043, USA.
| | | |
Collapse
|